Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer.
Only a small number of promising drugs target pancreatic cancer, which is the fourth leading cause of cancer deaths with a 5-year survival of less than 5%. Our goal is to develop a new biotherapeutic agent in which a lysosomal protein (saposin C, SapC) and a phospholipid (dioleoylphosphatidylserine,...
Main Authors: | Zhengtao Chu, Shadi Abu-Baker, Mary B Palascak, Syed A Ahmad, Robert S Franco, Xiaoyang Qi |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3790873?pdf=render |
Similar Items
-
Biotherapy of Brain Tumors with Phosphatidylserine-Targeted Radioiodinated SapC-DOPS Nanovesicles
by: Harold W. Davis, et al.
Published: (2020-08-01) -
SapC–DOPS as a Novel Therapeutic and Diagnostic Agent for Glioblastoma Therapy and Detection: Alternative to Old Drugs and Agents
by: Ahmet Kaynak, et al.
Published: (2021-11-01) -
SAPC 2021, persidangan antarabangsa mengupas tentang manfaat enau
by: Utusan Borneo Sarawak
Published: (2022) -
DOP coefficients in GNSS observations
by: Kamil Maciuk
Published: (2015-03-01) -
Study of the properties of NBR/PVC/DOP blends /
by: 320075 Kovacic, T., et al.